- MeSH
- diferenciální diagnóza MeSH
- kapilární hemangiom * diagnóza farmakoterapie patologie vrozené MeSH
- lidé MeSH
- novorozenec MeSH
- oční víčka * abnormality MeSH
- propranolol terapeutické užití MeSH
- Check Tag
- lidé MeSH
- novorozenec MeSH
- Publikační typ
- přehledy MeSH
Activated brown fat (aBAT) is known to affect the evaluation of 18F-FDG PET scans, especially in young patients. The aim of this study was to determine factors influencing the occurrence of aBAT, and to investigate the effectiveness of the two preventive measures, warming and beta-blocker (propranolol) administration. Five-hundred-twenty-eight 18F-FDG-PET scans of 241 EuroNet-PHL-C2 trial patients from 41 nuclear medicine departments in Germany and Czech Republic were screened for aBAT. The occurrence of aBAT was analyzed with patient characteristics (age, sex, body mass index, predisposition to aBAT), weather data at the day of 18F-FDG PET scanning as well as the preventive measures taken. Potentially important factors from univariate analyses were included into a logistic regression model. Warming as a preventive measure was used in 243 18F-FDG-PET scans, propranolol was administered in 36, warming and propranolol were combined in 84, and no preventive measures were taken in 165 scans. Whereas age, sex and body mass index had no clear impact, there was an individual predisposition to aBAT. Logistic regression model revealed that the frequency of aBAT mainly depends on the outside temperature (p = 0.005) and can be effectively reduced by warming (p = 0.004), the administration of unselective beta-blocker or the combination of both. Warming is a simple, cheap and non-invasive method to reduce the frequency of aBAT. However, the effect of warming decreases with increasing outside temperatures. Administration of propranolol seems to be equally effective and provides advantages whenever the positive effect of warming is compromised. The combination of both preventive measures could have an additive effect.
- MeSH
- beta blokátory farmakologie MeSH
- fluorodeoxyglukosa F18 * farmakologie MeSH
- hnědá tuková tkáň diagnostické zobrazování MeSH
- lidé MeSH
- lymfom * MeSH
- pozitronová emisní tomografie metody MeSH
- propranolol farmakologie MeSH
- radiofarmaka farmakologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- MeSH
- fatální výsledek MeSH
- hemangiom diagnóza farmakoterapie MeSH
- lidé MeSH
- nemoci svalů * diagnóza genetika MeSH
- neprospívání etiologie MeSH
- předškolní dítě MeSH
- propranolol terapeutické užití MeSH
- svalová slabost diagnóza etiologie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- kazuistiky MeSH
- MeSH
- dítě MeSH
- hemangiom * diagnóza farmakoterapie MeSH
- lidé MeSH
- propranolol terapeutické užití MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
Capillary electrophoresis-frontal analysis (CE-FA) together with mobility shift affinity CE is the most frequently used mode of affinity CE for a study of plasma protein-drug interactions, which is a substantial part of the early stage of drug discovery. Whereas in the classic CE-FA setup the sample is prepared by off-line mixing of the interaction partners in the sample vial outside the CE instrument and after a short incubation period loaded into the capillary and analysed, in this work a new methodological approach has been developed that combines CE-FA with the mixing of interacting partners directly inside the capillary. This combination gives rise to a fully automated and versatile methodology for the characterization of these binding interactions besides a substantial reduction in the amounts of sample compounds used. The minimization of possible experimental errors due to the full involving of sophisticated CE instrument in the injection procedure, mixing and separation instead of manual manipulation is another fundamental benefit. The in-capillary mixing is based on the transverse diffusion of laminar flow profile methodology introduced by Krylov et al. using its multi-zone injection modification presented by Řemínek at al.. Actually, after the method optimization, the alternate introduction of six plugs of drug and six plugs of bovine serum protein in BGE, each injected for 3 s at a pressure of -10 mbar (-1 kPa) into the capillary filled by BGE, was found to be the best injection procedure. The method repeatability calculated as RSDs of plateau highs of bovine serum albumin and propranolol as model sample compounds were better than 3.44 %. Its applicability was finally demonstrated on the determination of apparent binding parameters of bovine serum albumin for basic drugs propranolol and lidocaine and acid drug phenylbutazone. The values obtained by a new on-line CE-FA methodology are in agreement with values estimated by classic off-line CE-FA, as well as with literature data obtained using different techniques.
- MeSH
- hemangiom * diagnóza farmakoterapie patologie terapie MeSH
- kojenec MeSH
- laserová terapie MeSH
- lidé MeSH
- progrese nemoci MeSH
- propranolol * aplikace a dávkování MeSH
- recidiva MeSH
- ret patologie MeSH
- výsledek terapie MeSH
- Check Tag
- kojenec MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- kazuistiky MeSH
S infantilním hemangiomem se můžeme setkat u 5 až 10 % dětí do jednoho roku. Tento benigní cévní tumor charakterizují tři fáze růstu - proliferace, plató, involuce. Povrchové hemangiomy dosahují svoji maximální velikost v 6 až 8 měsících, u hlubokých vzácně až ve 2 letech. Moderní terapie neselektivnín β‑blokátorem - propranololem - nabízí dětem účinné, bezpečné a neinvaziní řešení. Pro efektivitu terapie je maximálně klíčové načasování zahájení terapie v proliferativní fázi.
Infantile hemangioma occurs in 5 to 10 % of children under one year of age. This benign vascular tumor is characterized by three phases of growth - proliferation, plateau, involution. Superficial hemangiomas reach their maximum size in 6 to 8 months, in deep ones rarely up to 2 years. Modern non-selective β-blocker therapy - propranolol - offers children an effective, safe and non-invasive solution. Starting the therapy in the proliferative phase is crucial for effectiveness.
- MeSH
- dítě MeSH
- hemangiom * diagnóza patofyziologie terapie MeSH
- lidé MeSH
- propranolol terapeutické užití MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- Publikační typ
- přehledy MeSH
- Klíčová slova
- infantilní hemangiomatóza, nádory benigní,
- MeSH
- farmakoterapie * kontraindikace využití MeSH
- hemangiom * diagnóza etiologie terapie MeSH
- kojenec MeSH
- lidé MeSH
- nádory jater diagnóza etiologie farmakoterapie MeSH
- nádory kůže diagnóza etiologie farmakoterapie MeSH
- nežádoucí účinky léčiv MeSH
- propranolol * aplikace a dávkování škodlivé účinky terapeutické užití MeSH
- statistika jako téma MeSH
- ultrasonografie metody využití MeSH
- výsledky a postupy - zhodnocení (zdravotní péče) MeSH
- Check Tag
- kojenec MeSH
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- kazuistiky MeSH
- Klíčová slova
- Sakrokokcigeální hemangiom,
- MeSH
- hemangiom * diagnóza etiologie terapie vrozené MeSH
- lidé MeSH
- novorozenec nedonošený MeSH
- propranolol aplikace a dávkování terapeutické užití MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- kazuistiky MeSH
